EU/3/17/1917: Orphan designation for the treatment of pancreatic cancer

Adenoviral vector of serotype 5 modified to contain a chimeric sequence consisting of a minimal urokinase-type plasminogen activator receptor promoter preceded by three Notch-responsive elements, and coated with oligopeptide end-modified poly (beta-amino) esters

Overview

On 16 October 2017, orphan designation (EU/3/17/1917) was granted by the European Commission to Sagetis Biotech, S.L., Spain, for adenoviral vector of serotype 5 modified to contain a chimeric sequence consisting of a minimal urokinase-type plasminogen activator receptor promoter preceded by three Notch-responsive elements, and coated with oligopeptide end-modified poly (beta-amino) esters (also known as SAG-101), for the treatment of pancreatic cancer.

Key facts

Active substance
Adenoviral vector of serotype 5 modified to contain a chimeric sequence consisting of a minimal urokinase-type plasminogen activator receptor promoter preceded by three Notch-responsive elements, and coated with oligopeptide end-modified poly (beta-amino) esters
Intended use
Treatment of pancreatic cancer
Orphan designation status
Positive
EU designation number
EU/3/17/1917
Date of designation
16/10/2017
Sponsor
Sagetis Biotech, S.L.
Via Augusta, 394
08017 Barcelona
Spain
Tel. +34 933097169
E-mail: xrivero@sagetis-biotech.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating